The Utility of Human Epididymal Protein 4, Cancer Antigen 125, and Risk for Malignancy Algorithm in Ovarian Cancer and Endometriosis
Authors:
- Aleksandar StefanovicASAleksandar Stefanovic
- Katarina JeremicKJKatarina Jeremic
- Milos M. RadojevicMRMilos M. Radojevic
- Ljubinka NikolicLNLjubinka Nikolic
- Ivanka MarkovicIMIvanka Markovic
- Jasmina AtanackovicJAJasmina Atanackovic
- 1 February 2012
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 22 (2) , 238-244
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Detection of the HE4 protein in urine as a biomarker for ovarian neoplasmsCancer Letters, 2010
- Current clinical use of biomarkers for epithelial ovarian cancerCurrent Opinion in Oncology, 2010
- Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal massGynecologic Oncology, 2010
- Development of a Multimarker Assay for Early Detection of Ovarian CancerJournal of Clinical Oncology, 2010
- Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort StudyJNCI: Journal of the National Cancer Institute, 2008
- Proteins with whey-acidic-protein motifs and cancerThe Lancet Oncology, 2006
- Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 2006
- Comprehensive analysis of HE4 expression in normal and malignant human tissuesLaboratory Investigation, 2006
- A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors1Biology of Reproduction, 1991
- Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant diseaseAmerican Journal of Obstetrics and Gynecology, 1988